US equities |
MU $1,065.88 ▼-2.03% NVDA $235.51 ▼-0.83% SNDK $1,637.65 ▼-3.24% PLTR $199.34 ▲+2.69% AMD $634.49 ▼-1.76% INTC $109.15 ▼-3.51% SPCX $163.50 ▼-2.45% META $720.03 ▼-0.18%
FinancialContent

Twist Bioscience Corporation - Common Stock (NQ:TWST)

152.56 -3.09 (-1.99%)
Delayed Quote Updated: 11:48 AM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Twist Bioscience Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Why Twist Bioscience Stock Skyrocketed This Week ↗
It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Twist Bioscience TWST Q2 Fiscal 2026: Revenue Beat Offset by Wider EPS Miss ↗
Via Chartmill
News headline image
Twist Bioscience (TWST) Q3 2026 Earnings Call Transcript ↗
AI-enabled drug discovery orders drive triple-digit growth as guidance rises. 
Via The Motley Fool
Topics Earnings
News headline image
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Sees AI Drug Discovery Pipeline Expand ↗
Twist Bioscience (NASDAQ: TWST) stock is up on strong Q3 results and raised guidance. AI drug discovery and NGS businesses show growth. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Twist Bioscience Q3 Earnings Call Highlights ↗
Twist Bioscience (NASDAQ:TWST) reported fiscal 2026 third-quarter revenue of $118.4 million, up 23% from a year earlier, marking its 14th consecutive quarter of growth. The company raised its full-year... 
Via MarketBeat
Topics Earnings
News headline image
Twist Bioscience Announces Fiscal 2026 Third Quarter Financial Results
From Twist Bioscience Corporation
Via Business Wire
News headline image
Cathie Wood Is Selling This High-Flying Stock. Is It a Buy? ↗
Wood's ETFs sell stocks that have had strong runs to pay for other positions. 
Via The Motley Fool
Topics ETFs
News headline image
Twist Bioscience to Report Fiscal 2026 Third Quarter Financial Results on Monday, August 3, 2026
From Twist Bioscience Corporation
Via Business Wire
News headline image
The Next Wave of Medical AI Could Mint More Millionaires Than the First -- Here Are the Stocks to Own ↗
AI's next winners in healthcare could be companies like Eli Lilly and Twist Bioscience. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors. ↗
This synthetic DNA specialist, leveraging silicon chip technology, reported a notable insider sale amid a year of strong share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors? ↗
This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Twist Biosciences' (TWST) CEO Sold 16,000 Shares for $1.1 Million ↗
This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist (TWST) Q2 2026 Earnings Call Transcript ↗
Twist (TWST) Q2 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Twist (TWST) Q3 2025 Earnings Transcript ↗
Twist (TWST) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience to Present at Upcoming Investor Conferences
From Twist Bioscience Corporation
Via Business Wire
News headline image
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
From Twist Bioscience Corporation
Via Business Wire
News headline image
Biotech Beat Nvidia in 2025. Can It Do It Again? ↗
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia? 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
From Twist Bioscience Corporation
Via Business Wire
News headline image
Cold Chain, High Stakes: A Deep Dive into Azenta’s (AZTA) Life Sciences Transformation
Date: February 5, 2026 Introduction In the high-stakes world of life sciences, the "cold chain" is the invisible backbone of modern medicine. From the development of mRNA vaccines to the emerging... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >